Skip to main content
logo
Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
72.60
+0.70 (0.97%)
Aug 17, 2026, 1:58 PM CST

TPEX:7427 Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.211.211.694.850.540.63
Revenue Growth
-32.34%-28.49%-65.26%798.15%-14.29%-
Gross Profit
-1.18-1.181.024.810.460.28
Operating Income
-99.54-99.54-112.65-65.82-68.79-36.52
Net Income
-97.47-97.47-104.92-61-67.13-35.86
Earnings Per Share
-2.26-2.26-2.55-1.68-2.78-1.70
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
447.54447.54582.76476.55247.58125.1
Total Debt
7.457.4510.3613.75--
Net Cash (Debt)
440.09440.09572.4462.8247.58125.1
Net Cash Growth
-10.49%-23.12%23.68%86.93%97.90%86.65%
Net Cash Per Share
10.2210.2213.8912.7610.255.93

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-87.56-87.56-76.85-54.99-77.17-33.92
Capital Expenditures
-0.28-0.28-2.11-2.93-0.05-0.04
Free Cash Flow
-87.84-87.84-78.96-57.92-77.21-33.96
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-98.26%-98.26%60.24%99.11%85.93%44.92%
Operating Margin
-8260.91%-8260.91%-6685.28%-1357.11%-12739.07%-5796.98%
Pretax Margin
-8089.05%-8089.05%-6226.94%-1257.67%-12431.85%-5691.59%
Profit Margin
-8089.05%-8089.05%-6226.94%-1257.67%-12431.85%-5691.59%
FCF Margin
-7289.46%-7289.46%-4685.82%-1194.21%-14298.70%-5389.68%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
2555.701140.63880.65528.303376.081485.29